Tasly Pharmaceutical Group Co Ltd - Asset Resilience Ratio
Tasly Pharmaceutical Group Co Ltd (600535) has an Asset Resilience Ratio of 11.69% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2025)
This chart shows how Tasly Pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. Check 600535 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Tasly Pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Tasly Pharmaceutical Group Co Ltd worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.83 Billion | 11.69% |
| Total Liquid Assets | CN¥1.83 Billion | 11.69% |
Asset Resilience Insights
- Moderate Liquidity: Tasly Pharmaceutical Group Co Ltd has 11.69% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Tasly Pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare Tasly Pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
JW Pharmaceutical Corp
KO:001067 |
Drug Manufacturers - Specialty & Generic | 8.17% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Guilin Sanjin Pharmaceutical Co Ltd
SHE:002275 |
Drug Manufacturers - Specialty & Generic | 14.80% |
|
Fuan Pharmaceutical Group Co
SHE:300194 |
Drug Manufacturers - Specialty & Generic | 1.34% |
|
DRI Healthcare Trust
TO:DHT-U |
Drug Manufacturers - Specialty & Generic | 13.91% |
|
Hainan Shuangcheng Pharmaceut
SHE:002693 |
Drug Manufacturers - Specialty & Generic | 1.03% |
Annual Asset Resilience Ratio for Tasly Pharmaceutical Group Co Ltd (2004–2025)
The table below shows the annual Asset Resilience Ratio data for Tasly Pharmaceutical Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 9.09% | CN¥1.39 Billion ≈ $204.00 Million |
CN¥15.34 Billion ≈ $2.24 Billion |
+5.58pp |
| 2024-12-31 | 3.50% | CN¥524.72 Million ≈ $76.78 Million |
CN¥14.98 Billion ≈ $2.19 Billion |
+1.70pp |
| 2023-12-31 | 1.80% | CN¥300.71 Million ≈ $44.00 Million |
CN¥16.71 Billion ≈ $2.45 Billion |
-5.05pp |
| 2022-12-31 | 6.85% | CN¥1.12 Billion ≈ $164.62 Million |
CN¥16.43 Billion ≈ $2.40 Billion |
-2.15pp |
| 2021-12-31 | 8.99% | CN¥1.49 Billion ≈ $217.66 Million |
CN¥16.54 Billion ≈ $2.42 Billion |
+8.13pp |
| 2020-12-31 | 0.87% | CN¥142.92 Million ≈ $20.91 Million |
CN¥16.49 Billion ≈ $2.41 Billion |
+0.62pp |
| 2019-12-31 | 0.25% | CN¥59.39 Million ≈ $8.69 Million |
CN¥24.01 Billion ≈ $3.51 Billion |
-0.38pp |
| 2018-12-31 | 0.63% | CN¥158.30 Million ≈ $23.16 Million |
CN¥25.17 Billion ≈ $3.68 Billion |
-1.94pp |
| 2017-12-31 | 2.57% | CN¥552.66 Million ≈ $80.87 Million |
CN¥21.53 Billion ≈ $3.15 Billion |
+1.00pp |
| 2016-12-31 | 1.56% | CN¥267.90 Million ≈ $39.20 Million |
CN¥17.13 Billion ≈ $2.51 Billion |
-0.19pp |
| 2015-12-31 | 1.76% | CN¥270.50 Million ≈ $39.58 Million |
CN¥15.41 Billion ≈ $2.26 Billion |
+1.39pp |
| 2014-12-31 | 0.36% | CN¥46.85 Million ≈ $6.86 Million |
CN¥12.92 Billion ≈ $1.89 Billion |
-0.47pp |
| 2013-12-31 | 0.83% | CN¥84.96 Million ≈ $12.43 Million |
CN¥10.21 Billion ≈ $1.49 Billion |
+0.58pp |
| 2012-12-31 | 0.25% | CN¥19.00 Million ≈ $2.78 Million |
CN¥7.49 Billion ≈ $1.10 Billion |
-0.36pp |
| 2006-12-31 | 0.61% | CN¥20.04 Million ≈ $2.93 Million |
CN¥3.26 Billion ≈ $477.01 Million |
-2.66pp |
| 2005-12-31 | 3.27% | CN¥90.08 Million ≈ $13.18 Million |
CN¥2.75 Billion ≈ $403.06 Million |
+2.82pp |
| 2004-12-31 | 0.46% | CN¥10.02 Million ≈ $1.47 Million |
CN¥2.20 Billion ≈ $322.08 Million |
-- |
About Tasly Pharmaceutical Group Co Ltd
Tasly Pharmaceutical Group Co., Ltd, together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers prescription drugs covering various therapeutic areas, including cardiovascular-cerebrovascular, tumor immunity, digestion and metabolism, and neuroscience; over-the-counter drugs; modern TCM; biological drugs; and chemical… Read more